My history with CYDY: In May, while hunting around for solutions to invest in that might help us out of this crisis, I found leronlimab. After reviewing the science to that point in time, I went all in on CytoDyn.Then I listened in on an investor update. The next day, I exited my position. I deeply regret that decision. Not simply because CYDY went to $10 a short while later. Dr. Pourhassan is rough around the edges, yes. But, he is passionate and dedicated and, above all else, honest and transparent. I love that. I love that so much. As a CEO myself and an investor, this resonates with me. I would be fairly comfortable with either Kelly or Rahman in charge. But I'm firmly behind Dr. Pourhassan staying in.